DataMEDS AI starts trading on Nasdaq under MEDS

DataMEDS AI began trading on the Nasdaq Capital Market under the new symbol MEDS on July 22, 2026, completing its rebrand from Wellgistics Health. The change comes as the company pushes ahead with acquisition and licensing plans tied to its AI, blockchain and health data platforms.

Why it matters: - The new Nasdaq symbol gives DataMEDS AI a cleaner market identity that matches its health-tech strategy. - The rebrand comes as the company is trying to position itself around artificial intelligence, blockchain-enabled health data, telemedicine and pharmacy-linked services. - Trading under MEDS may also make the company easier for investors to track after the name change from Wellgistics Health.

What happened: - DataMEDS AI began trading under the ticker MEDS on the Nasdaq Capital Market at the start of trading on Wednesday, July 22, 2026. - The symbol change completes the company’s corporate rebranding from Wellgistics Health, which traded as WGRX. - DataMEDS AI said it is focused on completing a previously disclosed series of acquisition and licensing transactions. - The company is a new B2i Digital Featured Company, with a listing on B2i Digital’s Featured Companies.

The details: - DataMEDS AI describes itself as a Health IT company built around its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contacts platform. - The company says those platforms are designed to support the generation, rationalization, intervention, transaction and monetization of health data. - DataMEDS AI says its Health Lives Here app is intended to connect medical, laboratory and wearable-device data into a proprietary blockchain-based health infrastructure. - The company says it is targeting patients affected by GLP-1-associated muscle loss and Long COVID. - DataMEDS AI says the platform is designed to let patients participate in data-transaction revenue, reduce data friction for providers and support tailored clinical trial offerings. - Interim Co-CEO Gerald Commissiong said the MEDS ticker is expected to draw attention from the health IT investment community. - Commissiong said the company intends to go beyond existing health IT platforms by offering adjunct natural products aimed at improving outcomes for GLP-1 patients and people with Long COVID. - Commissiong also said the Health Lives Here app is intended to capture biometric data and help patients better manage wearable-device data in healthcare decisions. - The company cited several market forecasts to support its thesis, including projected growth in blockchain healthcare, drone-enabled medical supplies delivery, GLP-1 drugs and telemedicine. - DataMEDS AI said it had 2,847,198 common shares outstanding as of the release date. - Stockholders holding about 1,533,930 shares, or a majority of the outstanding common shares, are under 90-day lock-up agreements. - The company said 919,465 common shares are deposited in DTCC and available for trading. - DataMEDS AI said it has no debt or preferred equity securities currently eligible to convert into free-trading common shares. - The company said 80,826 cash warrants remain outstanding, each with a $35.00 exercise price.

Between the lines: - The ticker change is more than administrative. It is part of a broader effort to reset the company’s market identity around a more expansive digital health story. - The emphasis on blockchain, patient data monetization and wearables suggests DataMEDS AI is trying to stand out in a crowded health IT market. - The heavy use of market-size projections signals an attempt to frame the company’s opportunity as tied to several fast-growing healthcare segments, though those forecasts are external estimates rather than company results.

What's next: - DataMEDS AI says it is working through the acquisition and licensing transactions it has already disclosed. - The company also pointed to planned development and expansion across EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms. - Forward-looking items in the release include a possible rebranding of the Pharmacy and Pharmacy Services division as Corexa Health and a proposed transaction involving DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors. - The company says investors should review its SEC filings for more detail on capitalization, outstanding securities and related risks.

The bottom line: - MEDS is now the public face of DataMEDS AI as the company tries to turn a stock symbol change into momentum for a broader health-tech strategy.